PTEN and Familial prostate cancer: As shown in Figure 4, in the Pten-mutated melanoma and Pten-null prostate cancer mouse model, the combination of PTEN mRNA nanoparticles (mPTEN@NPs) can reverse the inhibition of antitumor immune responses by increasing the infiltration of CD8+T and CD3+T cells, and can combine with anti-programmed death-1 (anti-PD-1) antibody enhancing the therapeutic efficacy (131).